TIME COURSE OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) DURING DOSTARLIMAB THERAPY IN THE GARNET TRIAL

被引：0

作者：

Pothuri, Bhavana ^{[1
,2
]}

Berton, Dominique ^{[3
,4
]}

Moreno, Victor ^{[5
]}

Oaknin, Ana ^{[6
]}

Perez, Jose Manuel Trigo ^{[7
]}

Curigliano, Giuseppe ^{[8
,9
]}

Ellard, Susan ^{[10
]}

Pikiel, Joanna ^{[11
]}

Banerjee, Susana ^{[12
,13
]}

Barretina-Ginesta, Maria-Pilar ^{[14
]}

Miller, Rowan ^{[15
]}

Tinker, Anna ^{[16
]}

Jewell, Andrea ^{[17
]}

Plummer, Ruth ^{[18
]}

Joly, Florence ^{[19
]}

Veneris, Jennifer ^{[20
]}

Duan, Tao ^{[20
]}

Andre, Thierry ^{[21
,22
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, Gynecol Oncol Grp GOG, New York, NY USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, Dept Obstet Gynecol, New York, NY USA

[3] Ctr Rene Gauducheau, GINECO, St Herblain, France

[4] Ctr Rene Gauducheau, Inst Cancerol Ouest, St Herblain, France

[5] Fdn Jimenez Diaz Hosp, START Madrid FJD, Madrid, Spain

[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[7] Hosp Virgen Victoria IBIMA, Med Oncol Dept, Malaga, Spain

[8] IRCCS, European Inst Oncol, IEO, Div Early Drug Dev Innovat Therapies, Milan, Italy

[9] Univ Milan, Milan, Italy

[10] BC Canc Kelowna, Kelowna, BC, Canada

[11] Reg Ctr Oncol, Gdansk, Poland

[12] Royal Marsden NHS Fdn Trust, London, England

[13] Inst Canc Res, London, England

[14] Hosp Univ Dr J Trueta, Inst Catala Oncol, Girona, Spain

[15] UCL, St Bartholomews Hosp London, London, England

[16] BC Canc, Vancouver, BC, Canada

[17] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[18] Newcastle Univ, Med Sch, Northern Inst Canc Res, London, England

[19] Ctr Francois Baclesse, Med Oncol Dept, Caen, France

[20] GlaxoSmithKline, London, England

[21] Sorbonne Univ, Paris, France

[22] St Antoine Hosp, Paris, France

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

370

引用

页码：A398 / A398

页数：1

共 50 条

[31] HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS
Doyle, S.
Lloyd, A.
Craig, A. M.
VALUE IN HEALTH, 2009, 12 (07) : A338 - A338
[32] SYSTEMATIC REVIEW ON TREATMENT-RELATED HAEMATOLOGICAL ADVERSE EVENTS AFTER TEMOZOLOMIDE FOR A CNS TUMOUR
Bos, Daniel
Gijtenbeek, Anja
Muller, Annemarie
Schouten-van Meeteren, Antoinette
NEURO-ONCOLOGY, 2018, 20 : 82 - 82
[33] Treatment-Related Adverse Events Recorded in Administrative Claims Compared to Electronic Medical Records
Irwin, Debra E.
Varker, Helen
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 560 - 561
[34] The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis
Al-Dakkak, Imad
Patel, Seema
McCann, Eilish
Gadkari, Abhijit
Prajapati, Girish
Maiese, Eric M.
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2013, 25 (04): : 400 - 414
[35] A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor
Sawada, Takashi
Narukawa, Mamoru
CANCER CONTROL, 2024, 31
[36] Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder
Papakostas, GI
Petersen, T
Hughes, ME
Nierenberg, AA
Alpert, JE
Fava, M
PSYCHIATRY RESEARCH, 2004, 126 (03) : 287 - 290
[37] Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer
Meng, Lingbin
Thapa, Ram
Delgado, Maria G.
Gomez, Maria F.
Ji, Rui
Knepper, Todd C.
Hubbard, Joleen M.
Wang, Xuefeng
Permuth, Jennifer B.
Kim, Richard D.
Laber, Damian A.
Xie, Hao
JAMA NETWORK OPEN, 2023, 6 (06) : E2320035
[38] Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events
Pinter, Matthias
Kwanten, Wilhelmus J.
Jain, Rakesh K.
CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3803 - 3812
[39] Treatment-related adverse events of antibody-drug conjugates: review of clinical toxicity
Reactions Weekly, 2022, 1935 (1) : 12 - 12
[40] COST OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) IN SECOND-LINE (2L) ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): MATCH ADJUSTED INDIRECT COMPARISON (MAIC) OF NIVOLUMAB AND REGORAFENIB
Venkatachalam, M.
Stenehjem, D.
Parikh, N. D.
Singh, P.
Marett, B.
Sill, B.
Wisniewski, T.
Prakash, V
Shukla, P.
Korytowsky, B.
Siddiqui, M. K.
VALUE IN HEALTH, 2017, 20 (09) : A502 - A503

← 1 2 3 4 5 →